Phaseline

Companies › Alterome Therapeutics

Alterome Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALTA2618
AKT1 E17K inhibitor
AKT1Phase 1CancerDec 2026
ALTA3263
KRAS G12C inhibitor
–Phase 1CancerMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06533059ALTA2618Phase 1CancerOncologyDec 2026
NCT06835569ALTA3263Phase 1CancerOncologyMay 2029

Targets

AKT1 (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Roche Laekna Zhejiang Haichang Biotech Atavistik Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.